A recent meta-analysis showed that PD-L1 expression is significantly associated with advanced tumor stages and that PD-L1 overexpression in immune cells, but not tumor cells, correlates with poorer survival, suggesting its use as a biomarker to stratify patients eligible for anti-PD1/L1 therapy [64]. Here, CD274 is linked to neoplasm.